Navigation Links
AlphaRx's Indaflex(TM) Continues its Clinical Development
Date:5/12/2008

MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that the clinical development of Indaflex(TM), its topical NSAID (Non-Steroidal Anti-Inflammatory Drug) formulation, will continue as part of Cypress Bioscience, Inc. ("Cypress') (NASDAQ: CYPB).

In March 2008, Cypress acquired Proprius Pharmaceuticals, Inc. ("Proprius"). The transaction included an upfront payment of approximately $37.5 million in cash, as well as an additional $37.5 million in potential milestone-related payments associated with the development of Proprius' therapeutic candidates including Indaflex(TM). AlphaRx was notified that the Indaflex licensing agreement has been assigned to Cypress from Proprius as part of that transaction.

Michael Lee, President of AlphaRx stated, "AlphaRx is excited to see the development of Indaflex continue as part of Cypress' on-going clinical development efforts. We believe Indaflex is in good hands and is consistent with Cypress's therapeutic focus and expertise."

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

Copyright @ 2008. AlphaRx Inc.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Battle Continues Over Vietnam PTSD Numbers
2. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
3. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
4. Securians Minnesota Life Continues to Climb Group Life Rankings
5. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
6. United States continues to have highest level of health spending
7. LehmanMillet Continues Expansion with Strategic Hires
8. American Cancer Society report finds breast cancer death rate continues to drop
9. CIGNA HealthCare Continues Gains in Health Care Quality
10. Los Angeles Jewish Home Support Group Continues High-Profile Speaker Program With Noted Legal Scholar and Expert Laurie L. Levenson
11. Volkswagen Continues Sponsorship of the Lasalle Bank Chicago Marathon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is ... in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly ... one roof. Smiles by Seese serves patients of all ages with excellence in general, ...
(Date:2/17/2017)... VA (PRWEB) , ... February ... ... FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 ... What are the critical reimbursement questions manufacturers should be asking before selecting ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program ... , Trinity Health and the U.S. Soccer Foundation announced today that they have ... communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals ...
(Date:2/17/2017)... GA (PRWEB) , ... February 17, 2017 , ... Like ... to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), ... been a key focus area for hospitals across the nation. While many providers are ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... 2017 Research and Markets has announced the addition ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:2/17/2017)... Conn. , Feb. 17, 2017 Arvinas ... of drugs based on protein degradation, today announced the ... receptor (AR) PROTAC during a poster session at the ... (ASCO GU) in Orlando, FL. ... to validate our platform and the potential of PROTACs ...
(Date:2/17/2017)... 2017   Risperdal lawsuits involving gynecomastia (male breast ... use of the atypical antipsychotic medication continue to move ... of Common Pleas, where the state,s Risperdal docket has ... a notice posted on the Court,s website , ... March 9, 2017 at 11:00 a.m. (In Re: Risperdal ...
Breaking Medicine Technology: